958 BNT211: a phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors

MLA

John Haanen, et al. “958 BNT211: A Phase I/II Trial to Evaluate Safety and Efficacy of CLDN6 CAR-T Cells and Vaccine-Mediated in Vivo Expansion in Patients with CLDN6-Positive Advanced Solid Tumors.” Journal for ImmunoTherapy of Cancer, vol. 9, no. Suppl 2, Nov. 2021. EBSCOhost, https://doi.org/10.1136/jitc-2021-SITC2021.958.

APA

John Haanen, Alexander Desuki, Andreas Mackensen, Ugur Sahin, Christian Koenecke, Winfried Alsdorf, Eva Wagner-Drouet, Daniel Heudobler, Peter Borchmann, Erol Wiegert, Catrine Schulz, Benjamin Rengstl, Liane Preussner, & Oezlem Tuereci. (2021). 958 BNT211: a phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors. Journal for ImmunoTherapy of Cancer, 9(Suppl 2). https://doi.org/10.1136/jitc-2021-SITC2021.958

Chicago

John Haanen, Alexander Desuki, Andreas Mackensen, Ugur Sahin, Christian Koenecke, Winfried Alsdorf, Eva Wagner-Drouet, et al. 2021. “958 BNT211: A Phase I/II Trial to Evaluate Safety and Efficacy of CLDN6 CAR-T Cells and Vaccine-Mediated in Vivo Expansion in Patients with CLDN6-Positive Advanced Solid Tumors.” Journal for ImmunoTherapy of Cancer 9 (Suppl 2). doi:10.1136/jitc-2021-SITC2021.958.